~" Arterial hypertension that occurs after severe head injury is characterized by elevation of systolic blood pressure, tachycardia, increased cardiac output, normal or decreased peripheral vascular resistance, and increased circulating catecholamines. The effects of two drugs used in the management of hypertension, propranolol and hydralazine, on these indices of cardiovascular function were examined in six head-injured patients. Both drugs effectively normalized blood pressure. However, hydralazine increased heart rate by 30%, cardiac index by 49%, left cardiac work by 21%, and pulmonary venous admixture by 53%, and was responsible for an increase in intracranial pressure or decreased compliance in two patients. Hydralazine produced no consistent change in arterial catecholamines. In contrast, propranolol decreased heart rate by 21%, cardiac index by 26%, left cardiac work by 35%, pulmonary venous admixture by 15%, and oxygen consumption by 18%. Propranolol decreased arterial epinephrine levels by 48% and norepinephrine levels by 28%. Propranolol appears to be a useful antihypertensive drug in the hyperdynamic head-injured patient because it normalizes blood pressure and the underlying hemodynamic abnormalities both by its betaadrenergic blocking action and by decreasing circulating levels of catecholamines.
S
YSTOLIC hypertension may be an important cause of secondary injury in head-injured patients. Cerebral autoregulation is frequently abnormal following head injury so that cerebral blood flow (CBF) rises or falls passively with changes in systolic blood pressure.~~ Arterial hypertension may then result in an increase in intracranial pressure (ICP) and cause further injury. Maintaining or reducing systolic blood pressure (BP) to below 160 mm Hg has been recommended to prevent secondary injury. Vasodilating drugs, which are commonly used for the treatment of essential hypertension, have been recommended for this purpose.~ i However, unlike the situation with essential hypertension in which patients have a normal cardiac output and an increased systemic vascular resistance, patients who are hypertensive following head injury have been found to have an increased cardiac output and a normal to decreased systemic vascular resistance. 2'~7 Because of the differences in the hemodynamics of the hypertension, antihypertensive drugs used to treat essential hypertension might not be as effective, or may even be deleterious in the hypertension associated with head injury. Feibel, et al., 7 reported that hypertension in patients who had high catecholamine excretion following acute intracranial hemorrhage was often refractory to vasodilating drugs such as nitroprusside and hydralazine, but easily controlled with propranolol. In addition, it is possible that vasodilating drugs could exaggerate the cardiopulmonary abnormalities that are present in patients who have sustained a severe head injury.
This study was designed to examine the hemodynamic changes and sympathetic response to hydralazine and to propranolol in patients with sustained hypertension following severe head injury.
Clinical Material and Methods
The six patients who were studied were managed in a similar manner. If ICP was elevated, it was controlled with hyperventilation, mannitol, and ventricular drainage. If the patient was agitated, he was sedated, and if he was spontaneously posturing, he was sedated and paralyzed. This series includes six patients who had resting systolic BP's of greater than 160 mm Hg after ICP control and sedation or paralysis. None of the patients was known to have essential hypertension. Details of the type and severity of injury are shown in Table 1 .
Definitions of Abbreviations avDO2 = arteriovenous oxygen difference BP = blood pressure CBF = cerebral blood flow CW = cardiac work E = epinephrine HR = heart rate ICP = intracranial pressure NE = norepinephrine O2ER = oxygen extraction ratio PCWP = pulmonary capillary wedge pressure QS/QT = pulmonary venous admixture SVR = systemic vascular resistance VO2 = oxygen consumption All six patients had a ventriculostomy tube, a radial or femoral arterial catheter, and a Swan-Ganz catheter placed. Baseline measurements of ICP, arterial BP, heart rate (HR), pulmonary artery pressure, central venous pressure, pulmonary capillary wedge pressure (PCWP), cardiac output, hemoglobin, arterial pO2 (PaO2), arterial epinephrine (E) and norepinephrine (NE) levels, and mixed venous pO2 were obtained before each drug was given, then repeated 30 minutes after the hydralazine was given and 10 minutes, 6 hours,
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and 24 hours after the loading dose of propranolol. In addition to ICP, the pressure-volume index was measured in Case 1 before and 30 minutes after administration of hydralazine. Cardiac index, systemic vascular resistance (SVR), left cardiac work (CW), pulmonary venous admixture (QS/QT), oxygen consumption (VO2), arteriovenous oxygen content difference (avDO2), and oxygen extraction ratio (O2ER) were calculated. Radioenzymatic assay was used to measure E and NE levels.
If there was no contraindication in terms of a marked tachycardia, hydralazine was given as the initial antihypertensive drug in a dose of 10 mg intravenously (IV), then 5 mg IV every 10 minutes until systolic BP was less than 160 mm Hg or the total dose was 40 mg. After BP returned to pretreatment levels, propranolol was given IV at a rate not greater than 1 mg/min until systolic BP was less than 160 mm Hg, HR was less than 55 beats/min, the cardiac index was less than 2.5 liters/ min/sq m, or PCWP was greater than 18 mm Hg. Antihypertensive effect was maintained with intermittent IV doses or continuous IV infusion of propranolol at a rate of approximately 20% of the loading dose per hour.
Summary data are reported as the mean + standard error of the mean (SEM). The hemodynamic and cat- 
Results
The Table 2 . The VO2 of the patients as a group was only slightly elevated because of the effect of sedation and paralysis on their motor activity, and was higher when measured without sedation or paralysis. The low avDO2 and O2ER indicated that their cardiac output was excessive for their metabolic demands. Cases 5 and 6 had a contraindication to hydralazine FIG. 1. Average hemodynamic parameters before and after administration of hydralazine (in four patients) and propranolol (in five). * = p < 0.05; ** = p < 0.01. The shaded areas represent the normal ranges. administration (that is, a baseline H R greater than 110 beats/min), so these patients did not receive this drug. Hydralazine lowered both systolic and diastolic BP in all four patients so treated, and none required more than 20 mg (Table 3) . One patient (Case 2) was given only 10 mg of hydralazine, although more would have been required to lower his systolic BP to less than 160 m m Hg, because he had an abrupt increase in his ICP to 33 m m Hg within 5 minutes of receiving the first dose. Figure 1 shows the average changes in the most significant h e m o d y n a m i c parameters after hydralazine administration in Cases 1 to 4. Although SVR was decreased by 45%, the decrease in CW resulting from lowering BP was more than offset by the increase in HR of 30% and in the cardiac index of 49%, and the work of the heart as estimated by left CW actually increased by 21%. Hydralazine also worsened the pulmonary ventilation-perfusion inequality already present, increasing QS/QT by 53% and lowering PaO2 by 28%. In Case 1, the PaO2 dropped from 158 to 87 mm Hg after hydralazine. Oxygen consumption did not change significantly, so the increase in the hyperdynamic state after hydralazine was even more inappropriate to metabolic demands than before. In Case 2, ICP was increased, and, although ICP did not change in Case 1, the pressure-volume index was decreased after hydralazine administration. There were no consistent changes in E or NE levels after hydralazine was given, although the tendency was for the catecholamines to be increased (Fig. 2) .
Propranolol was given in Cases 5 and 6 as the initial antihypertensive drug and in Cases 1, 2, and 3 when the BP returned to prehydralazine levels, at 10, 4, and 5 hours after hydralazine administration, respectively. One patient (Case 4) never received propranolol because he was taken to surgery for evacuation of a hematoma shortly after receiving hydralazine, and was not hypertensive postoperatively. Propranolol primarily decreased systolic BP in all five patients (Table 4) , although the dose required varied considerably, from 5 to 26 mg. The response of the diastolic BP was variable. Figure 1 shows the changes in the major hemodynamic parameters with propranolol: HR decreased by 21% and the cardiac index by 26%. There was no significant change in SVR, thus, left CW decreased by 35%. Propranolol decreased QS/QT by 15%. In Cases I to 3 and 6, with near normal VO2 but elevated cardiac index, propranolol decreased the cardiac index more than VO2, and thus increased avDO2 from a mean of 2.94 + 0.53 ml/dl to 3.41 __+ 0.62 ml/dl, and O2ER from 17 ___ 3% to 20 + 3%. In Case 5, the only patient who FIG. 2. Average arterial catecholamine levels before and after administration of hydralazine (in four patients) and propranolol (in five). * = p < 0.05; ** = p < 0.01. The shaded areas represent the normal ranges.
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had an extremely high metabolic rate and a cardiac index that appeared appropriate for the high metabolic demand, propranolol decreased VO2 more than the cardiac index and decreased avDO2 from 7.29 to 4.10 ml/dl. Thus, in all cases so treated, propranolol changed the cardiac index and VO2 so that balance between tissue metabolic requirements and oxygen delivery, as indicated by avDO2 and OzER, was more normal. Propranolol was not associated with ICP changes in any patient. These hemodynamic changes are associated with a decrease in arterial catecholamine levels ( Fig. 2 ): E was decreased by 48% and NE by 28%.
Discussion
The onset of action of a number of antihypertensive agents is rapid enough to be useful in the treatment of the hypertension associated with head trauma. The peripheral vasodilating drugs have a very rapid onset of action; they include diazoxide, hydralazine, nitroprusside, and nitroglycerin. The drugs that primarily act centrally as an alpha-agonist, namely methyldopa and clonidine, have an onset of action of about 30 minutes, but still may be useful in some urgent situations. When hypertension is due to increased sympathetic activity, propranolol, a beta-blocking drug, can be given IV for a rapid response.
If one goal of treating systemic hypertension in the head-injured patient is to prevent the increase in CBF that occurs with hypertension when cerebral autoregulation is abnormal, then the vasodilating antihypertensive drugs may not be the best choice. Vasodilators, including hydralazine, have been associated with increases in ICP and neurological deterioration in patients with intracranial mass lesions, presumably by causing dilation of cerebral capacitance vessels. 4' 5'4 In addition, hydralazine causes dilation of cerebral resistance vessels and increases CBF. 14 Two of the four patients given hydralazine in this study had adverse effects on their ICP, even though BP was lowered.
If a second goal of treating systemic hypertension in the head-injured patient is to resolve the cardiopulmonary abnormalities, then the vasodilating antihypertensive drugs are not the best choice. In these patients, although hydralazine lowered BP, CW was actually increased, and hydralazine worsened pulmonary ventilation-perfusion inequality.
Hydralazine is known to exacerbate symptoms of angina in hypertensive patients with ischemic heart disease by increasing CW. 9 Although most head-injured patients do not have coronary artery disease, they may still have relative myocardial ischemia if myocardial oxygen demand exceeds oxygen supply. Elevated levels of the myocardial isoenzyme of creatine kinase, in over 90% of patients who have sustained a severe head injury, and autopsy findings of subendocardial necrosis in 50% of patients who die of their brain injury, suggest that ischemia frequently occurs. 8 The clinical significance of these laboratory findings is not clear, but patients with persistently low cardiac outputs following head trauma have a poor prognosis. ~5 Hydralazine resulted in an increase in CW and thus increased myocardial oxygen demand in each patient in this study.
Patients with head injury commonly have ventilation-perfusion inequality, and occasionally have abnormal shunting from pulmonary edema. ~8' 2~ In these settings, arterial vasodilators are known to increase QS/ QT by increasing blood flow to poorly ventilated or nonventilated areas of the lung? Hydralazine caused consistent increases in QS/QT and decreases in PaO2 in these patients.
An ideal antihypertensive drug for head-injured patients would lower BP without increasing ICP, and would normalize the adverse cardiopulmonary changes. A drug that either decreases the sympathetic hyperactivity or blocks the effect of the increased sympathetic activity on the heart should achieve these goals. The beta-blocking drug, propranolol, has these properties, but may also have more complex, and in some cases, adverse effects. For example, in normal man propran-0101 may increase plasma catecholamine levels. However, its effect on plasma catecholamines appears to depend upon the pathology being treated. In some hyperadrenergic states, such as during the evolution of an acute myocardial infarction, propranolol can blunt the increase in plasma catecholamines that usually occurs, and will decrease HR and cardiac index. '2 However, in another hyperadrenergic disease, pheochromocytoma, treatment of hypertension with propranolol has resulted in either no change or an increase in BP, left ventricular failure, and acute pulmonary edema. 2j Another concern about using propranolol in head-injured patients is that because metabolic needs are often increased, lowering cardiac output might result in inadequate delivery of oxygen. However, in the patients reported here, propranolol lowered systolic BP and blunted the other cardiopulmonary effects of severe head injury. Cardiac index and HR, and thus left CW and myocardial oxygen demand, were always decreased after propranolol administration, but without producing heart failure or pulmonary edema. Pulmonary ventilation-perfusion inequality was usually improved by propranolol. Although the cardiac index was always decreased after propranolol, VO2 was also decreased so that the lower cardiac index remained adequate for metabolic needs, as measured by a normal or low O2ER and avDO2.
The present data suggest that the mechanism of action of propranolol in the patients studied was more complex than a simple blocking of the beta-adrenergic effects of the high levels of circulating catecholamines, since propranolol also actually decreased catecholamine levels. There is considerable experimental evidence that the release of NE from the postganglionic sympathetic nerve terminal is regulated by a presynaptic feedback system. Norepinephrine, released from the varicosities of the nerve ending as a result of nerve activity, stimulates alpha and/or beta adrenoceptors located on the cell membrane of the target organ. The released NE also produces negative feedback by stimulating alpha receptors on the membrane of the varicosities of the presynaptic nerve ending. This decreases the amount of NE released by each nerve impulse. ~9 In contrast, some evidence suggests that stimulation of beta receptors on the presynaptic nerve ending produces positive feedback and increases release of NE.~ If this positive feedback process is active in states in which there is a high level of circulating NE, such as in head injury, blocking the stimulation of the presynaptic beta receptors with propranolol would be expected to produce a fall in circulating NE values, as we observed.
There is also evidence supporting an action of propranolol on the central nervous system which may play a role in the present findings. Propranolol is lipophilic, and after IV injection can be found in the brain at a concentration many times that of plasma. 6 Intraven-
TABLE 4
Hemodynamic and arterial catecholamine response to propranolol* tricular propranolol causes decreased BP, 16 and IV propranolol causes inhibition of tonic and evoked sympathetic discharges that correlate with the decreased Bp.~3
This study was not designed to examine the effect of reducing BP or of blocking excessive sympathetic activity on outcome following head trauma. Control of hypertension has been recommended in the treatment of head injury by some authors as a means of decreasing CBF and ICP. ~ This recommendation has been based on data in animals and has never been examined in man. ~~ Consequently, the present results should not be interpreted as a recommendation to treat all hypertensive head-injured patients with propranolol or even to treat hypertension in head injury. Based on the data presented here, the use of vasodilator therapy in head injury is a questionable practice. Extensive research involving CBF studies will be required to evaluate the use of antihypertensive therapy, which has become widely accepted in the treatment of head injury.
